CAFFEINE CONSUMPTION PATTERNS AND BELIEFS OF COLLEGE FRESHMEN

Recently, energy drinks that contain high caffeine content without any age restrictions for purchase, have been introduced into the U.S. market. Caffeine consumption in the U.S. has increased dramatically, resulting in an increase in emergency room visits and calls to poison control centers. This increase in energy drink consumption, along with the traditional coffees, teas, and soft drinks that people consume regularly, have pushed caffeine consumption to new highs in a multi-billion dollar market. The purpose of this study was to determine (1) the amount of caffeine consumed by a sample of freshmen students at Marshall University, (2) their beliefs regarding caffeine consumption, (3) reported perceived benefits and adverse effects of caffeine consumption, (4) reasons for consuming or refraining from consuming caffeine, and (5) predictors of high and low caffeine consumption. Eighty three percent reported having at least one sign/symptom of caffeine intoxication in the past while 51% reported having at least one sign/symptom of caffeine withdrawal. More than 78% consumed above the recommended 200mg of caffeine per day. The mean milligram of caffeine consumed per day in the present study was 849.86, which computes to 12.08 mg/kg/day. This was three to five times the recommended amount. Father’s social index, participation in organized activity in college, and three items for concentration, keep awake, and wake up (items of alertness) were statistically significant predictors of caffeine consumption. Respondents that participated in organized activity while in college consumed on average 60.7% more caffeine than those who indicated they did not participate in organized activity while in college. Every time the three items for concentration, keep awake, and wake up increased one point, caffeine consumption increased on average 41.1%. Females were more likely to believe that caffeine is addictive than their male counterparts. Beliefs of negative consequences of caffeine consumption did not deter caffeine consumption. Slightly more than 60% reported using caffeine to wake up in the morning and more than 76% reported using it to stay awake. This was consistent with reported beliefs of the effects of caffeine consumption. Implications for education were discussed

Youth throwing athletes do not show bilateral differences in medial elbow width or flexor tendon thickness

Background: Medial elbow laxity develops in throwing athletes due to valgus forces. Medial elbow instability in professional, collegiate, and high school athletes is well documented; however, the medial elbow of young throwing athletes has received less attention. This study investigated the medial elbow and common flexor tendon during applied elbow valgus stress of youth baseball players. Methods: The study included 15 participants. The medial elbow width and thickness of the common flexor tendon were measured on ultrasound images. Results: No significant side differences in medial elbow width or common flexor tendon were found at rest or under applied valgus stress. At rest, the medial elbow joint width was 3.34±0.94 mm on the dominant side and 3.42±0.86 mm on the non-dominant side. The dominant side increased to 3.83±1.02 mm with applied valgus stress, and the non-dominant side increased to 3.96±1.04 mm. The mean flexor tendon thickness was 3.89±0.63 mm on the dominant side and 4.02±0.70 mm on the non-dominant side. Conclusions: These findings differ from similar studies in older throwing athletes, likely because of the lack of accumulated stress on the medial elbow of youth throwing athletes. Maintaining elbow stability in young throwing athletes is a vital step to preventing injury later in their careers

WAY-855 (3-amino-tricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake

1. The pharmacological profile of a novel glutamate transport inhibitor, WAY-855 (3-amino-tricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid), on the activity of the human forebrain glutamate transporters EAAT1, EAAT2 and EAAT3 expressed in stable mammalian cell lines and in Xenopus laevis oocytes is presented. 2. WAY-855 inhibited glutamate uptake mediated by all three subtypes in a concentration-dependent manner, with preferential inhibition of the CNS-predominant EAAT2 subtype in both cells and oocytes. IC(50) values for EAAT2 and EAAT3 inhibition in cells were 2.2 and 24.5 μM, respectively, while EAAT1 activity was inhibited by 50% at 100 μM (IC(50) values determined in oocytes were 1.3 μM (EAAT2), 52.5 μM (EAAT3) and 125.9 μM (EAAT1)). 3. Application of WAY-855 to EAAT-expressing oocytes failed to induce a transporter current, and the compound failed to exchange with accumulated [(3)H]D-aspartate in synaptosomes consistent with a nonsubstrate inhibitor. WAY-855 inhibited D-aspartate uptake into cortical synaptosomes by a competitive mechanism, and with similar potency to that observed for the cloned EAAT2. 4. WAY-855 failed to agonise or antagonise ionotropic glutamate receptors in cultured hippocampal neurones, or the human metabotropic glutamate receptor subtype 4 expressed in a stable cell line. 5. WAY-855 represents a novel structure in glutamate transporter pharmacology, and exploration of this structure might provide insights into the discrimination between EAAT2 and other EAAT subtypes

hnRNP-Q1 represses nascent axon growth in cortical neurons by inhibiting Gap-43

Posttranscriptional regulation of gene expression by mRNA-binding proteins is critical for neuronal development and function. hnRNP-Q1 is an mRNA-binding protein that regulates mRNA processing events, including translational repression. hnRNP-Q1 is highly expressed in brain tissue, suggesting a function in regulating genes critical for neuronal development. In this study, we have identified Growth-associated protein 43 (Gap-43) mRNA as a novel target of hnRNP-Q1 and have demonstrated that hnRNP-Q1 represses Gap-43 mRNA translation and consequently GAP-43 function. GAP-43 is a neuronal protein that regulates actin dynamics in growth cones and facilitates axonal growth. Previous studies have identified factors that regulate Gap-43 mRNA stability and localization, but it remains unclear whether Gap-43 mRNA translation is also regulated. Our results reveal that hnRNP-Q1 knockdown increased nascent axon length, total neurite length, and neurite number in mouse embryonic cortical neurons and enhanced Neuro2a cell process extension; these phenotypes were rescued by GAP-43 knockdown. Additionally, we have identified a G-quadruplex structure in the 5′ untranslated region of Gap-43 mRNA that directly interacts with hnRNP-Q1 as a means to inhibit Gap-43 mRNA translation. Therefore hnRNP-Q1–mediated repression of Gap-43 mRNA translation provides an additional mechanism for regulating GAP-43 expression and function and may be critical for neuronal development